Jefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
BioMarin (BMRN) PT Raised to $120 at Piper Jaffray
August 5, 2016 9:01 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $120.00 (from $107.00) following Q2 results and raised guidance.
Schimmer commented, "After the close, BMRN reported strong 2Q results and raised FY2016... More
BioMarin Pharma's (BMRN) Q2 Revenue Tops Views
August 4, 2016 4:08 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($2.61), may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $300.1 million versus the consensus estimate of $278.16 million.
GUIDANCE:
BioMarin Pharma sees FY2016 revenue of $1.1-1.15 billion,... More
Trading Radar for 8/4: Kellogg (K), MGM Resorts (MGM), Activision (ATVI), FireEye (FEYE), Weight Watchers (WTW) Report
August 3, 2016 2:51 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
AAC Holdings (NYSE: AAC) - consensus EPS $0.23
AGCO Corp. (Nasdaq: AGCO) - consensus EPS $0.92
ANI Pharma (Nasdaq: ANIP) - consensus EPS $0.77
Acceleron Pharma (NYSE: XLRN) - consensus loss $0.50
Agios Pharma (Nasdaq:... More
